3-D stem cell culture technique developed to better understand Alzheimer’s disease

Apr. 2, 2013 A team of researchers at The New York Stem Cell Foundation Research Institute led by Scott Noggle, PhD, Director of the NYSCF Laboratory and the NYSCF -- Charles Evans Senior Research Fellow for Alzheimer's Disease, and Michael W. Nestor, PhD, a NYSCF Postdoctoral Research Fellow, has developed a technique to produce three-dimensional cultures of induced pluripotent stem (iPS) cells called embryoid bodies, amenable to live cell imaging and to electrical activity measurement.

As reported in their Stem Cell Research study, these cell aggregates enable scientists to both model and to study diseases such as Alzheimer's and Parkinson's disease.

The NYSCF Alzheimer's disease research team aims to better understand and to find treatments to this disease through stem cell research. For such disorders in which neurons misfire or degenerate, the NYSCF team creates "disease in a dish" models by reprogramming patients' skin and or blood samples into induced pluripotent stem (iPS) cells that can become neurons and the other brain cells affected in the diseases.

The cells in our body form three-dimensional networks, essential to tissue function and overall health; however, previous techniques to form complex brain tissue resulted in structures that, while similar in form to naturally occurring neurons, undermined imaging or electrical recording attempts.

In the current study, Noggle and Nestor with NYSCF scientists specially adapted two-dimensional culture methods to grow three-dimensional neuron structures from iPS cells. The resultant neurons were "thinned-out," enabling calcium-imaging studies, which measure the electrical activity of cells like neurons.

"Combining the advantages of iPS cells grown in a 3D environment with those of a 2D system, our technique produces cells that can be used to observe electrical activity of putative networks of biologically active neurons, while simultaneously imaging them," said Nestor. "This is key to modeling and studying neurodegenerative diseases."

Neural networks, thought to underlie learning and memory, become disrupted in Alzheimer's disease. By generating aggregates from iPS cells and comparing these to an actual patient's brain tissue, scientists may uncover how disease interferes with these cell-to-cell interactions and understand how to intervene to slow or stop Alzheimer's disease.

"This critical new tool developed by our Alzheimer's team will accelerate Alzheimer's research, enabling more accurate manipulation of cells to find a cure to this disease," said Susan L. Solomon, CEO of NYSCF.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

View original post here:
3-D stem cell culture technique developed to better understand Alzheimer's disease

Experience beautifying benefits of a ‘ stem cell facial’ at MD Beauty Labs

Stem cell therapy has been used by doctors since as early as the 16th century to heal damaged cells and/or tissue. In the past 10 years, modern medicine has again started using this process, instead of chemicals to treat illness and/or suppress it.

A new stem cell facial therapy uses stem cells derived from sheeps placenta. The placenta and umbilical cord tissue cells are ethically harvested from sheep, post birth so there is absolutely no harm to animals.

The pluripotent stem cells are extremely nutrient-rich, and very similar to embryonic stem cells. This means that they have the ability to repair every type of cell in the body.

When applied in sufficient concentrations, large numbers of bio-active stem cells immediately de-age the skin by stimulating the dermal layer to produce increased levels of collagen and elastic fibers.

This can be described as skin food that provides cellular renewal, reduces inflammation and hydrates the skin.

Its a new skin rejuvenation treatment that produces results comparable to those derived from skin-rejuvenating lasers but without the extended recovery period or steep cost.

The treatment is delivered via a device called the Eclipse micropen. This automated microneedling instrument vertically penetrates the outer layer of skin with a vibrating motion. The techniques pinpoint delivery system stimulates revitalizing collagen production, minus the downtime associated with other collagen-increasing protocols.

Since the needling is automated, patient discomfort is also minimized.

Before the microneedling, the patients skin is numbed with a topical anaesthetic. Next, highly effective medical, topical serums or creams are applied to the skin, depending on the each individual patients needs.

For example, bleaching creams are used for patients with hyperpigmentation or hyaluronic acid for hydration and plumping of the skin.

View post:
Experience beautifying benefits of a ‘ stem cell facial’ at MD Beauty Labs

Andain Inc. Discusses and Provides Update on its Breakthrough Stem Cell Therapy for the Treatment and Regeneration of …

ARAD, Israel, April 2, 2013 /PRNewswire/ --

Andain Inc. (ANDN) ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its incubator program, today discussed and provided an update on its breakthrough, innovative stem cell therapy for treating and regenerating severely damaged muscle tissue.

Andain's innovative stem cell therapy technology rehabilitates and heals damaged muscle tissue by initiating regenerative myogenic cells (cardiac muscle), as well as striated muscle cells (skeletal muscle) growth in damaged tissue sites such as the myocardium (cardiac muscle) following an myocardial infarction (heart attack), limb pressure ulcers, and degenerative muscular diseases. The short term application is directed towards the treatment of patients with peripheral vascular disease, while the long term application is focused on the healing and regeneration of cardiac muscle following acute myocardial infarction or chronic heart failure.

Employing a patient's own cells (autologic transplantation), the Company's unique technology and process diverts the patient's own cells into specific targeted myogenic cells, which can then be inserted into the damaged tissue and accelerates the healing process. The administered myogenic or skeletal stem cells work as a network, acting in exactly the same way that the cells of skeletal and heart muscle tissue perform, and actually replenish the existing cells, thus strengthening the intended injured site following the transplantation process. This process can be utilized for different clinical pathologies as mentioned above and can also be utilized for patient using different donor as the source of the stem cells.

Our developed technology and protocols results in a promising safe regenerative therapy, without side effects, tissue rejection or the requirement of suppressive immunological treatment or malignant tumor hazard. Our technology also provides a simple, fast and safe treatment, overcoming technological difficulties associated with using other stem cell therapies sources such as embryonic, placenta, or umbilical cord blood cells that require cryogenic storage.

Andain's President and CEO Sam Elimelech, commented, "The field of stem cell therapeutics is in its early stages of growth as companies and researchers continue to uncover the vast potential and promising uses for them in the treatment and prevention of countless tissue injuries and diseases. We are in an excellent position to capitalize on the emergence of this new market. It is our belief that Orcell's cutting-edge technology and process is unique in regard to the fact that it allows for the safe and efficient directing of the patients own cells as into myogenic cells or striated muscle cells, thus eliminating the hazards associated with rejection and malignant tumors. Via our industrial incubator platform and expert scientific team, we look forward to helping Orcell commence their clinical trials later this year and make considerable progress of their technology and process closer to market."

Andain's incubator platform is currently undergoing with its stem cell technology a build-up of GLP (Good Laboratory Practice) production line as a preparation for the FDA approval stage with clinical trials scheduled for Q1 2014 at one of the foremost Heart centers in Israel under the direction of Professor Mickey Scheinowitz, one of Israel's leading scientists who gained vast experience in the understanding and treating of cardiovascular diseases.

ABOUT ANDAIN INC

Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain (OTC: ANDN) commercializes novel technologies in the biotech, medical and life sciences fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value. For more information, please visit our website at http://www.andaininc.com.

FORWARD LOOKING STATEMENTS

Originally posted here:
Andain Inc. Discusses and Provides Update on its Breakthrough Stem Cell Therapy for the Treatment and Regeneration of ...

Spas, salons warned on stem cell therapy

By Tina G. Santos Philippine Daily Inquirer

MANILA, PhilippinesStem cell therapy at spa centers and salons? Watch out, government agents are coming.

Health Secretary Enrique Ona says no clinic or hospital in the Philippines can offer stem cell therapy without accreditation from the Department of Health (DOH).

Speaking to reporters last week, Ona noted that while many centers are advertising stem cell therapy treatment, none of them have the approval of the health department.

As of now we have not accredited any clinic or even hospital offering stem cell therapy yet, Ona said.

Admitting that the DOH doesnt have the police power to close down erring health centers, Ona said the department would coordinate with other governmental agencies like the Department of Trade and Industry (DTI) and local governments to prevent spas and salons from offering stem cell treatment.

We will issue a warning for them to stop [doing stem cell therapy]. But if they continue despite warnings from us, thats when we will move to close them down, Ona said.

Stem cell therapy and treatment, which are becoming popular here and abroad, are medical procedures that deal with ailments by replacing malignant cells with healthy cells.

Only medical doctors with the right training can perform stem cell treatment.

Cosmetic purposes

View post:
Spas, salons warned on stem cell therapy

Italy pushes on with controversial stem cell therapy

Italian health officials are allowing a handful of patients to continue with a controversial stem cell therapy amid protests from scientists that the treatments are unproven and unsafe.

The Stamina Foundation has been administering the therapy at the public hospital Spedali Civili of Brescia to people with a range of degenerative diseases. Their approach is based on mesenchymal stem cells, derived from bone marrow, which can become mature bone and connective tissue.

In 2011 the hospital agreed to host the research and assist with cell extraction and patient treatments, stirring protests from the medical community. "The hospital is not even listed among the 13 Italian authorised stem cell factories," says Michele de Luca, director and gene therapy programme coordinator at the Centre for Regenerative Medicine in Modena. After an inspection in 2012, Italian drug regulator AIFA ordered an immediate halt to Stamina's stem cell treatments at the hospital.

The AIFA report says the Stamina Foundation's treatment did not follow Italy's official path required for clinical approval. So far no scientific publications describing its effectiveness are available.

But the halt sparked protests among patients' families who believed the treatment was working. Some appealed to the courts, and as a result a few patients were allowed to go ahead with the therapy. On 15 March, a group of 13 Italian stem cell researchers published an open letter to the country's Minister of Health, Renato Balduzzi, asking him to shut down all of the Stamina Foundation's treatments at the hospital.

Instead Balduzzi signed a bill last week authorising the foundation to continue treatments in patients who had already begun the regime unless they are experiencing serious side effects.

If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.

Only subscribers may leave comments on this article. Please log in.

Only personal subscribers may leave comments on this article

Subscribe now to comment.

Read the original:
Italy pushes on with controversial stem cell therapy

Scientists Slam Italy’s Untested Stem Cell Therapy

ROME -- European scientists are criticizing a decision by Italy's government to allow a handful of children to be treated in public hospitals with an experimental stem cell therapy.

The adult stem cell treatment was halted in May by the Italian Pharmacological Agency. But the government last week overruled the regulator after parents went to court to demand that the therapy be continued. The health ministry, citing ethical and compassionate concerns, said the therapy shouldn't be interrupted since it hadn't shown any "grave collateral effects" in the children, some of whom are terminally ill.

In a letter to Italy's health minister, Renato Balduzzi, more than a dozen scientists criticized the decision, saying it "seems to be dictated by emotions raised by public opinion rather than scientifically based reasons."

The decision to allow the unproven therapy by the Stamina Foundation, which is based in Italy, came despite findings from a police search, including inspectors from the Italian Pharmacological Agency, at the laboratory where the stem cell treatments were being prepared.

In May, the agency ordered all work at the Stamina Foundation laboratory to stop after finding that conditions were "absolutely inadequate." The inspectors said there were "terrible maintenance and cleanliness conditions" that couldn't guarantee the cells weren't contaminated. The agency also said the doctors administering the adult stem cell treatment weren't aware of what they were injecting and the patients' medical records didn't detail the therapies.

Adult stem cells can maintain and repair tissues within a person, but there is no known benefit of removing such cells and using them to treat patients. Most research into stem cells concerns embryonic stem cells, often considered controversial because they involve the destruction of embryos. Embryonic stem cells can produce a wide variety of specialized cells, and scientists are working to harness them as repair kits for diseases, including Parkinson's and diabetes. By comparison, adult stem cells have a more limited ability to turn into other types of body tissue and are more likely to contain abnormalities than those derived from embryos. Balduzzi defended the decision to allow the treatment and described it as a "compassionate" ruling. He said it would only continue in public hospitals or research clinics under strict monitoring with the consensus of an ethics committee. The government ruling covers patients already receiving the Stamina Foundation treatment, those who had begun preparatory procedures such as the cultivation of cells, or those who by court order had been authorized to begin the treatment. "The decision of the government to authorize the continuation of therapies ordered by judges was necessary to prevent discrimination, based on autonomous decisions by judges, between patients who had begun treatment with the Stamina Method," Balduzzi said.

Several British scientists said the Italian decision set a dangerous precedent and could even encourage desperate patients to seek treatment abroad. "If politicians, doctors or patient organizations ignore the facts, they may unwittingly become party to exploitation of the most vulnerable members of society by approving meaningless `treatments,'" Austin Smith, director of the Cambridge Stem Cell Institute, said in a statement. Steve Dunnett, a stem cell expert at the University of Cardiff, said it was worrying that no details on the experimental procedure or its results in patients had been published. "Our starting position has to be that the marketing is a scam to which the correct response should indeed be to refuse a license and certainly not pay for a spurious treatment out of the public purse," Dunnett said in a separate statement.

See the original post here:
Scientists Slam Italy's Untested Stem Cell Therapy

Stem cell fate depends on ‘grip’

Mar. 28, 2013 The field of regenerative medicine holds great promise, propelled by greater understanding of how stem cells differentiate themselves into many of the body's different cell types. But clinical applications in the field have been slow to materialize, partially owing to difficulties in replicating the conditions these cells naturally experience.

A team of researchers from the University of Pennsylvania has generated new insight on how a stem cell's environment influences what type of cell a stem cell will become. They have shown that whether human mesenchymal stem cells turn into fat or bone cells depends partially on how well they can "grip" the material they are growing in.

The research was conducted by graduate student Sudhir Khetan and associate professor Jason Burdick, along with professor Christopher Chen, all of the School of Engineering and Applied Science's Department of Bioengineering. Others involved in the study include Murat Guvendiren, Wesley Legant and Daniel Cohen.

Their study was published in the journal Nature Materials.

Much research has been done on how stem cells grow on two-dimensional substrates, but comparatively little work has been done in three dimensions. Three-dimensional environments, or matrices, for stems cells have mostly been treated as simple scaffolding, rather than as a signal that influences the cells' development.

Burdick and his colleagues were interested in how these three-dimensional matrices impact mechanotransduction, which is how the cell takes information about its physical environment and translates that to chemical signaling.

"We're trying to understand how material signals can dictate stem cell response," Burdick said. "Rather than considering the material as an inert structure, it's really guiding stem cell fate and differentiation -- what kind of cells they will turn into."

The mesenchymal stem cells the researchers studied are found in bone marrow and can develop into several cell types: osteoblasts, which are found in bone; chondrocytes, which are found in cartilage; and adipocytes, which are found in fat.

The researchers cultured them in water-swollen polymer networks known as hydrogels, which share some similarities with the environments stem cells naturally grow in. These materials are generally soft and flexible -- contact lenses, for example, are a type of hydrogel -- but can vary in density and stiffness depending on the type and quantity of the bonds between the polymers. In this case, the researchers used covalently cross-linked gels, which contain irreversible chemical bonds.

When seeded on top of two-dimensional covalently cross-linked gels, mesenchymal stem cells spread and pulled on the material differently depending on how stiff it was. Critically, the mechanics guide cell fate, or the type of cells they differentiate it into. A softer environment would produce more fat-like cells and a stiffer environment, where the cells can pull on the gel harder, would produce more bone-like cells.

Follow this link:
Stem cell fate depends on 'grip'

Scientists criticize Italy for allowing unproven stem cell therapy

Scientists have criticized an Italian government decree allowing a group of terminally-ill patients to continue using an unproven stem cell treatment, saying such therapies may cause harm and risk exploiting desperate people.

The treatment, created by the privately-owned Stamina Foundation, was banned by Italian medicines regulator AIFA last year after it inspected their laboratories, leading to a series of legal challenges by families of patients.

In early March, Health Minister Renato Balduzzi allowed a terminally ill child to continue using the Stamina treatment after hearing the emotional pleas of her parents.

Related: Catholic Church gives its blessing to stem cell research in new book

The Health Ministry then issued an official decree on March 21 allowing 32 patients, mainly children, already using the treatment to continue it.

Scientists from around Europe released a statement on Thursday criticizing the decree, warning that Balduzzi was "riding roughshod over existing European licensing criteria", failing to protect patients from exploitation and ignoring the need for sound evidence that therapies are effective.

"These unproven and ill-prepared stem cell therapies, for which there is no scientific basis, will do nothing for patients and their families except make them poorer," said Charles French-Constant from the University of Edinburgh's Center for Regenerative Medicine.

'Dangerous precedent'

Advocates of the therapy say strict regulations work in favor of big drug companies with their portfolio of blockbuster treatments, reducing the pool of potential competitors. But scientists said Stamina's treatment was unproven and risky.

"There is no rationale for this and no evidence that these procedures are not dangerous for patients," said Professor Michele De Luca of the University of Modena.

Read the original:
Scientists criticize Italy for allowing unproven stem cell therapy

Part 18, after stem cell treatment, Feeling better again, 24march2013 – Video

Part 18, after stem cell treatment, Feeling better again, 24march2013
My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it #39;s in the family of Muscular Dystrophy. I re...

By: Kina Diamond

The rest is here:
Part 18, after stem cell treatment, Feeling better again, 24march2013 - Video

Lifespan opens stem cell research lab in Knowledge District

PROVIDENCE Lifespan opened a new stem cell research laboratory Wednesday afternoon on the fifth floor of the hospital networks Coro Building. The lab is the first phase of a major investment to turn the entire building in Providences Knowledge District into a state-of-the art research facility.

Construction of the new 11,000-sqare-foot research lab, a Center for Biomedical Research Excellence for Stem Cell Biology, was funded through a $300,000 National Institutes of Health grant to Dr. Peter Quesenberry, director of hematology oncology at Rhode Island and The Miriam hospitals.

The lab will provide researchers with the state-of-the-art technology needed to support ongoing research in the areas of cancer, tissue injury and basic stem cell biology, according to Quesenberry.

This new lab space will help us to further study the use of stem cells for the treatment of many illnesses various forms of cancer, tissue and organ damage and much more, Quesenberry said. Creating this research hub provides our researchers with the best possible resources, and places us in close proximity to the hospitals, allowing us to more appropriately collaborate with our peers, and truly bring research from the bench to the bedside.

The laboratory also will support research in novel anti-cancer treatments for pediatric and adult malignancies, and will continue to examine therapeutic mechanisms underlying refractory leukemia and lymphoma, according to hospital officials. The new lab space can accommodate 14 laboratory benches, and can accommodate 10 funded investigators, as well as their technicians and students.

Part of Rhode Island Hospitals mission is to be at the forefront of patient care by creating, applying and sharing the most advanced knowledge in health care, said Peter Snyder, senior vice president and chief of research at Lifespan. One of the ways we do that is by providing our researchers with the tools they need to conduct cutting-edge research in order to discover and create improved diagnostic measures and treatments.

This new research space is the first step in a major renovation project of the 270,000-square-foot Coro Building, creating a research facility that will serve as a focal point for clinical research in Rhode Island, according to Snyder.

Notable elected officials speaking at the labs opening and tour included Gov. Lincoln D. Chafee, Lt. Gov. Elizabeth H. Roberts, U.S. Sens. Jack Reed and Sheldon Whitehouse, U.S. Rep. James R. Langevin, and Providence Mayor Angel Taveras.

Speakers from the Rhode Island medical community included Dr. Edward Wing, dean of medicine and biological sciences at The Warren Alpert Medical School at Brown University, Dr. Timothy J. Babineau, president and CEO of Lifespan, Snyder, Quesenberry, and Dr. Louis Rice, chief of the department of medicine at Rhode Island and The Miriam hospitals.

See the rest here:
Lifespan opens stem cell research lab in Knowledge District